Skip to content

Eloralintide vs Tirzepatide

Updated 6 sources

Key differences

  1. 1In the type 2 diabetes phase 2 at 48 weeks: eloralintide 6 mg alone -12.3%, tirzepatide 15 mg -14.8%, both together up to -23.3%.
  2. 2Tirzepatide is FDA approved (Zepbound, Mounjaro); eloralintide is in phase 3.

Side by side

Facts from each record, in the same words as their own pages.
Eloralintide and Tirzepatide side by side
EloralintideTirzepatide
Category
  • Weight loss
  • GLP-1, Weight loss
Evidence
  • Some human trials
  • Strong human trials
FDA status
  • In clinical trialsRegulatory
  • FDA approved as Mounjaro +1Regulatory
WADA
  • Not confirmed
  • Not prohibited
Half-life
  • About 13 to 15 days (310 to 366 hours) after single doses of 0.04 to 12 mg in healthy adults; levels peak 72 to 132 hours after a shot.Clinical study
  • About 5 days (Mounjaro label); 5 to 6 days in people with obesity or sleep apnea (Zepbound label). That is why it is dosed once a week.Regulatory
Routes
  • Subcutaneous injection
  • Subcutaneous injection
Forms
  • Vial (powder)
Not reported
Reported doses
  • 0.5 to 12 mg (subcutaneous injection)
  • 0.25 to 15 mg (subcutaneous injection)
Most cited frequency
  • Once weekly at 1, 3, 6 or 9 mg depending on arm
  • Once weekly. Step up 2.5 mg after at least 4 weeks only if needed, then hold the maintenance dose.
Vial sizes
  • 10 mg, 30 mgVendor guide
  • 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mgCompetitor guide
Mixed vial keeps
  • Fridge at 2 to 8 °C, protected from light.Vendor guide
  • Keep the mixed vial in the fridge and use it within about 28 days.Competitor guide
Protocols on file
  • 8
  • 12

Doses shown are what sources report, labelled by origin. Not medical advice.

Read each in full

Sources

6 sources, each checked by date. Record updated Oct 24, 2026. Numbers are restated in our own words and labelled by where they came from.